On the 1 February 2017, Australia joined the US and Europe in making continuous therapy with Revlimid (lenalidomide) plus dexamethasone reimbursed on the Pharmaceutical Benefits Scheme for newly diagnosed transplant ineligible patients with multiple myeloma1. This is exciting news, and the limbic spoke with Dr Hang Quach, Consultant Haematologist at St Vincent’s Hospital, Melbourne, and ...
Continuous therapy in multiple myeloma: its about time
4 Jul 2017
Sponsored by Celgene Pty Ltd